ANKRD30A and neoplasm: Since CD8+ T cells are considered as primary effector cells in tumor immune surveillance along with the fact that this T cell subset was overrepresented in NY-BR-1 expressing tumors, we set out to identify NY-BR-1-specific CD8+ T cell epitopes that might be involved in CTL recognition of NY-BR-1 expressing tumor cells.